# Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

> **NCT00967096** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 20 (actual)

## Conditions studied

- Malignancy
- Bone Marrow Transplantation

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT00967096
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967096, "Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00967096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*